骨肉瘤
Bone sarcoma
注意：这个中文名不唯一。ORPHA:668 在 Orphanet 中文包里用的是同一个中文名，但它们是不同的疾病实体——请对照英文名与 ORPHA 编号确认你要找的是哪一个。
基本事实
- 患病率
- 1-9 / 1 000 000（Europe）
相关基因 1来自下位疾病
Orphanet 未在本条目上直接标注致病基因。下表由本组所属的下位疾病汇总而来，「来源条目」列给出基因实际标注在哪一个 ORPHA 条目上。
| 基因 | 名称 | 来源条目 |
|---|---|---|
| TP53 | tumor protein p53 | ORPHA:668 |
近两年的全球研究 16,468L2
2024/08 起在 Europe PMC 检索所得，按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务，尚未引入。
- 2026-09综述Virtual Surgical Planning and Clinical 3D Printing from Medical Imaging for Orthopedic, Hand, and Spine Surgery
- 2026-09Not all NTRK fusions in mesenchymal neoplasia are driver events: implications on classification and targeted therapy
- 2026-09病例报告Computed Tomographic Findings of Primary Hepatic Extraskeletal Osteosarcoma With Peritoneal Metastasis via Periportal Space in a Dog
- 2026-09Fe<sub>3</sub>O<sub>4</sub> nanoparticles suppress osteosarcoma via macrophage reprogramming and the MIP-1α-CCL3 axis
- 2026-08病例报告Concurrent Germline RB1 & Mosaic TP53 in a Child With Multiple Childhood Cancers
- 2026-08Nuclear localized p70S6K maintain cancer stem-like properties by modulating RPA3 activity in osteosarcoma
- 2026-08Morphine modulates doxorubicin-induced genomic instability with distinct effects in osteosarcoma and fibroblast cells
- 2026-08Outcomes of hemicortical resection and reconstruction with liquid nitrogen-treated autograft for high-grade sarcomas: A retrospective case series
- 2026-08Fibulectomy for primary fibular tumors A Decade of experience at the National Cancer Institute, Egypt
- 2026-08CircHMGB2 Acts as a Molecular Decoy for IGF2BP1 to Promote Cisplatin Resistance via Grb10/Akt Signaling in Chondrosarcoma
- 2026-08综述Targeting USP7 in sarcomas: opportunities and challenges
- 2026-08Stromal Cells Recruitment by Sono-Piezoelectric/Pyroelectric Peptide Hydrogels Promotes Bone Regeneration After Postsurgical Osteosarcoma Recession: A Real-World-Matched Study
- 2026-08Pulmonary metastasectomy in Iceland: Long-term nationwide trends and outcomes
- 2026-08病例报告First clinical isolation of <i>Purpureocillium lilacinum</i> in a pediatric oncological patient in Ecuador
- 2026-08Self-powered electro-activated Mg<sub>x</sub>Fe<sub>1-x</sub>S<sub>2</sub> scaffold for gas-ion therapy in osteosarcoma suppression and bone regeneration
- 2026-08A single-molecule prodrug synergistically suppresses MYC-amplified osteosarcoma through sequential nitric oxide release and photodynamic therapy
- 2026-08Bispecific ANXA2/CD147 CAR-T cell therapy for osteosarcoma
- 2026-08Upregulation of paraoxonase-2 enzyme in human osteosarcoma and its involvement in mechanisms promoting the aggressive behavior of tumor cells
- 2026-08病例报告Chondroid Soft Tissue Tumors With FOS::PABPN1 Fusion: A New Entity? About Two Cases
- 2026-08Reducing complications after resection of pelvic bone sarcomas : an aggregation of marginal gains
境外已获批用于本病的药物 4L2
欧盟 1 项、美国 3 项。同一药物在两地各批一次的，会分别列出。
「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径，各有各的条件与费用。这一节能确定地告诉你的只有一件事：这个病在世界范围内已经有获得批准的药物，它叫什么名字。拿这个名字去问主治医生，是下一步最省力的做法。
药名一律保留英文原文，不作翻译——中国的药品通用名与英文名的音译经常不一致，译错会让人去找一个不存在的药。
- Mepact欧盟2009-03-06mifamurtide官方记录
- Methotrexate美国1988-04-07Methotrexate sodium官方记录
- Leucovorin calcium美国1988-08-31Leucovorin官方记录
- Fusilev美国2008-03-07Levoleucovorin官方记录
已获孤儿药资格、尚未获批的在研药物（38 项）
孤儿药资格只是一种监管身份——它意味着监管机构认可这是罕见病用药并给予研发激励，不代表这个药已被证明有效，也不代表将来一定能上市。绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
- cisplatin欧盟2013-08-05Treatment of osteosarcoma官方记录
- live attenuated Listeria monocytogenes bioengineered with a chimeric h欧盟2015-12-14Treatment of osteosarcoma官方记录
- (E)-2-((2S,4S)-4-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-欧盟2019-12-16Treatment of osteosarcoma官方记录
- toll-like receptor 4 agonist欧盟2022-08-10Treatment of osteosarcoma官方记录
- vactosertib欧盟2023-07-25Treatment of osteosarcoma官方记录
- domatinostat欧盟2026-01-09Treatment of osteosarcoma官方记录
- sirolimus欧盟2026-01-09Treatment of osteosarcoma官方记录
- Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gy美国1998-06-10Treatment of osteosarcoma.官方记录
- mifamuritide美国2001-06-05Treatment of osteosarcoma官方记录
- SDF-1 (108) Lysine Dlmer美国2005-07-07Treatment of osteogenic sarcoma官方记录
- Cisplatin in liposomal formulation美国2007-03-20Treatment of osteosarcoma官方记录
- 5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin美国2007-06-15Treatment of osteosarcoma (bone cancer)官方记录
- Mx-dnG1美国2008-06-24Treatment of osteosarcoma.官方记录
- monoclonal antibody Hu3F8美国2014-01-10Treatment of osteosarcoma官方记录
- live attenuated bioengineered Listeria monocytogenes immunotherapy美国2014-05-21Treatment of osteosarcoma.官方记录
- Anti-STAT3 B VHH13 single domain antibody美国2017-09-27Treatment of osteosarcoma官方记录
- 18-(p-[131I]-iodophenyl)octadecyl phosphocholine美国2018-09-24Treatment of osteosarcoma官方记录
- Humanized connexin 43 (hCx43) monoclonal antibody美国2019-09-18Treatment of Osteosarcoma官方记录
- dual E-selectin and C-X-C chemokine receptor Type 4 (CXCR4) antagonist美国2020-01-27Treatment of osteosarcoma官方记录
- (R)-2-allyl-1-(7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2美国2020-10-14Treatment of osteosarcoma官方记录
- humanized secreted frizzled-related protein-2 monoclonal antibody美国2020-10-15treatment of osteosarcoma官方记录
- a highly purified unmodified carbohydrate polymer which consists of (1美国2020-10-21Treatment of Osteosarcoma官方记录
- Pirarubicin美国2020-10-29Treatment of osteosarcoma官方记录
- Samarium (Sm-153) chelate of DOTMP (1,4,7,10-tetraazacyclododecane-1,4美国2021-08-11Treatment of osteosarcoma官方记录
- vactosertib美国2021-08-27Treatment of osteosarcoma官方记录
- Lutetium-177 labeled humanized monoclonal antibody targeting leucine r美国2022-09-07Treatment of osteosarcoma (OS)官方记录
- a genetically modified Salmonella comprising of methioninase美国2022-11-08Treatment for osteosarcoma官方记录
- tegavivint美国2022-11-22Treatment of Osteosarcoma官方记录
- dovitinib美国2023-10-11Treatment of Osteosarcoma官方记录
- Glycine, L-prolyl-L-prolyl-L-leucyl-L-seryl-L-glutaminyl-L-alpha-gluta美国2023-12-28Treatment of Osteosarcoma官方记录
- Cinnamtannin B-1美国2024-02-05Treatment of Osteosarcoma官方记录
- certepetide美国2024-03-28Treatment of Osteosarcoma官方记录
- doxorubicin hydrochloride美国2025-07-14treatment of osteosarcoma官方记录
- attenuated Salmonella typhimurium containing the gene for human interl美国2025-11-19treatment of osteosarcoma官方记录
- type C cytidine phosphate guanosine- oligodeoxynucleotide (CpG-ODN) to美国2025-12-31treatment of osteosarcoma官方记录
- 10,11- methylenedioxy-20(S)-camptothecin美国2026-04-23treatment of osteosarcoma官方记录
- LRRC15-directed monoclonal antibody conjugated to a linker-payload, mo美国2026-05-28treatment of osteosarcoma官方记录
- domatinostat美国2026-07-30treatment of osteosarcoma官方记录
数据来自欧洲药品管理局（EMA）的药品与孤儿药资格公开导出表，以及美国 FDA 孤儿药资格数据库。两边口径不同：欧盟一侧取的是当前状态仍为「已授权」的药品；美国一侧记录的是「曾获批准」这一事实，FDA 的公开表不追踪药物此后是否退市（例如 Relyvrio 于 2024 年撤市，表中仍记为已获批）。请以官方记录页为准。
在中国开展的临床试验 95L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实，并与主治医生商量。
登记为可入组 35
- 招募中NCT04072042BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma中国研究中心 1 个：Shanghai
- 招募中NCT04589741Toripalimab Combined With CAV/IE Regimen中国研究中心 1 个：Guangzhou
- 尚未开始招募NCT05590572A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma中国研究中心 4 个：Beijing、Jinan、Shanghai
- 招募中NCT05617859Lenvatinib for Advanced Bone and Soft Tissue Sarcoma中国研究中心 1 个：Zhengzhou
- 招募中NCT06074692PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)中国研究中心 1 个：Shanghai
- 招募中NCT06114225Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial中国研究中心 1 个：Shanghai
- 招募中NCT05830123ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas中国研究中心 11 个：Beijing、Changsha、Guangzhou、Hangzhou、Nanjing、Shanghai 等 8 地
- 招募中NCT06126510Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma中国研究中心 1 个：Beijing
- 尚未开始招募NCT06041490Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation中国研究中心 1 个：Beijing
- 招募中NCT06778603B7-H3 NIR Imaging for Osteosarcoma Surgery中国研究中心 1 个：Beijing
- 招募中NCT06111612Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement中国研究中心 1 个：Shanghai
- 招募中NCT06340204Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma中国研究中心 3 个：Beijin、Beijing、Jina
- 招募中NCT06637007Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma中国研究中心 1 个：Taiyuan
- 尚未开始招募NCT06550765Safety and Efficacy of Degradable Magnesium Metal Clips in Surgical Margins of Radical Surgery for Malignant Bone and Soft Tissue Tumors中国研究中心 1 个：Guangzhou
- 招募中NCT07648069Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma中国研究中心 1 个：Guangzhou
- 招募中NCT06564272A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma中国研究中心 1 个：Beijing
- 招募中NCT06699472A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib中国研究中心 1 个：Shanghai
- 招募中NCT06714383Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma中国研究中心 1 个：Beijing
- 招募中NCT07602049Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma中国研究中心 1 个：Guangzhou
- 尚未开始招募NCT06836765The Relationship Between The Differential Expression Of FosB Protein In Laryngeal Cancer Tissues And Clinical Prognosis中国研究中心 1 个：Nanchong
- 招募中NCT06827717Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma中国研究中心 1 个：Guangzhou
- 招募中NCT06926283A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors中国研究中心 4 个：Beijing、Changsha、Hangzhou
- 招募中NCT07066982Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas中国研究中心 1 个：Beijing
- 尚未开始招募NCT07142863Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients中国研究中心 1 个：Shanghai
- 招募中NCT07725783Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma中国研究中心 1 个：Beijing
另有 10 项未列出。
其他状态的试验（60 项）
- 已完成NCT06162962Oncological and Functional Outcomes in Lower Limb Osteosarcoma Pediatric Patient中国研究中心 1 个：Guangzhou
- 已终止NCT00568464Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)中国研究中心 1 个：Shanghai
- 状态未知NCT01002092A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma中国研究中心 4 个：Beijing、Jinan、Nanjing、Xi’an
- 状态未知NCT01669369Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma中国研究中心 1 个：Guangzhou
- 已完成NCT03491371Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use中国研究中心 2 个：Beijing
- 已完成NCT057945943D Printed Personalized Extendable Prosthesis中国研究中心 1 个：Chongqing
- 已完成NCT02711007Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy中国研究中心 1 个：Beijing
- 进行中·不再招募NCT02650401Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options中国研究中心 2 个：Beijing、Shanghai
- 状态未知NCT03932071Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma中国研究中心 1 个：Hangzhou
- 状态未知NCT03163381Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.中国研究中心 1 个：Zhengzhou
- 状态未知NCT03108677Circulating Exosome RNA in Lung Metastases of Primary High-Grade Osteosarcoma中国研究中心 1 个：Shanghai
- 已完成NCT03742063Clinical Evaluation of Neoadjuvant Chemotherapy for Primary Malignant Sarcomas That Originate in Bone中国研究中心 2 个：Beijing
- 状态未知NCT03336554Epigenetic Biomarker for Osteosarcoma中国研究中心 1 个：Beijing
- 已完成NCT03359018Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma中国研究中心 2 个：Beijing
- 状态未知NCT03358992Clinical Evaluation for Sarcoma Originated From Bone中国研究中心 3 个：Beijing、Hangzhou、Xi'an
- 状态未知NCT03416517Anlotinib and Irinotecan for Ewing Sarcoma中国研究中心 5 个：Beijing
- 状态未知NCT03359005Irinotecan and Temozolomide for Ewing Sarcoma中国研究中心 1 个：Beijing
- 已完成NCT03462316NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma中国研究中心 1 个：Guangzhou
- 状态未知NCT03582527PD-L1 Expression in Advanced Osteosarcoma中国研究中心 1 个：Beijing
- 状态未知NCT03539172Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study中国研究中心 1 个：Shanghai
- 状态未知NCT03360760Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum中国研究中心 1 个：Beijing
- 状态未知NCT03932058Proteomics Research of Osteosarcoma中国研究中心 1 个：Hangzhou
- 状态未知NCT03676985A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma中国研究中心 1 个：Shanghai
- 已完成NCT03909776Transcatheter Intra-arterial Limb Infusion of Cisplatin for Extremity Osteosarcoma中国研究中心 1 个：Beijing
- 状态未知NCT03742193Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy中国研究中心 1 个：Shanghai
- 已完成NCT03997747Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OS中国研究中心 2 个：Beijing
- 已撤回NCT04044378Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma中国研究中心 1 个：Beijing
- 状态未知NCT04074564MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma中国研究中心 1 个：Shanghai
- 状态未知NCT03919539Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab中国研究中心 1 个：Beijing
- 状态未知NCT04461223Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR中国研究中心 1 个：Hangzhou
- 状态未知NCT04294511Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma中国研究中心 1 个：Guangzhou
- 已完成NCT04546243Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective Study中国研究中心 2 个：Beijing
- 状态未知NCT04351308Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma中国研究中心 1 个：Beijing
- 状态未知NCT04690725TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss中国研究中心 1 个：Beijing
- 已完成NCT05101655Construction of Microfluidic Exosome Chip for Diagnosis of Lung Metastasis of Osteosarcoma中国研究中心 1 个：Shanghai
- 已完成NCT04690231Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma中国研究中心 1 个：Beijing
- 状态未知NCT05194605Predictive Models of Treatment Responses and Survival Outcomes in Patients With Osteosarcoma中国研究中心 1 个：Chengdu
- 已暂停NCT04824352Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma中国研究中心 2 个：Beijing
- 已终止NCT04861948IBI188 Combination Therapy in Solid Tumors中国研究中心 1 个：Tianjin
- 已终止NCT04900766A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma中国研究中心 1 个：Beijing
另有 20 项未列出。
中国境外的在招试验 185L2
这些试验在中国没有研究中心，通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处：看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生，或据此进一步查该药是否已在境外获批、是否有拓展性用药（expanded access）通道。
美国103意大利15法国10荷兰8加拿大8澳大利亚5西班牙5德国5比利时3巴西3英国3土耳其2中国台湾2捷克2另有 21 个国家/地区
CT.gov 报告命中 185 项，此处取回并展示最近的 15 项。
- 尚未开始招募NCT06988007Bone Arches: Performance of Pseudo-scanner Sequences in Segmenting the Extent of the Tumour and in Planning Surgical Resection Using the CT Scan as a Reference比利时
- 尚未开始招募NCT07695311EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT美国
- 尚未开始招募NCT07516353my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults美国
- 尚未开始招募NCT07729059"Exercise Intervention to Increase Physical Activity in Young Sarcoma Survivors (Sport Ist Herzenssache)"
- 尚未开始招募NCT07662239Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention美国
- 尚未开始招募NCT07514819Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma美国
- 尚未开始招募NCT07560826The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma美国
- 招募中NCT07727434Stress and Anxiety Before Biopsy, After Biopsy Results, and During Treatment in Patients With Suspected Bone or Soft Tissue Cancer土耳其
- 招募中NCT07211737NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma美国
- 招募中NCT07725380Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma美国
- 尚未开始招募NCT07619950EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma
- 尚未开始招募NCT07636148Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance法国、荷兰
- 招募中NCT06492954Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma美国
- 招募中NCT07502885Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer Patients美国
- 招募中NCT07321912Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma美国
外部标识与链接
发现这一页有错误？告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学：Orphanet（CC BY 4.0）
- 中文病名：Orphanet 中文包，冻结于 2020-06-01
- 表型中文标签：HPO 简体中文翻译（CHPO 上游成果）